Drug Trial Radar · NCT02484547
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Sep 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,643
Actual
Start
Sep 15, 2015
Primary completion
Aug 5, 2019
Study completion Aug 5, 2019
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jun 29, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) \[ADAS-Cog 13\], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) \[ADCS-ADL-MCI\].
Conditions
- Alzheimer's Disease
Interventions
Aducanumab (BIIB037)Drug
Low dose
Aducanumab (BIIB037)Drug
High dose
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 78Time frame: Baseline, Week 78
Locations
180 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Banner Alzheimer's Institute
Phoenix, Arizona
Xenoscience Inc.
Phoenix, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
Institute for Memory Impairments
Irvine, California
Renewal Behavioral Health
Long Beach, California
USC Keck School of Medicine
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Excell Research, Inc.
Oceanside, California
Pacific Neuroscience Medical Group
Oxnard, California
Anderson Clinical Research
Redlands, California
Pacific Research Network
San Diego, California
University of California San Diego Medical Center
San Diego, California
California Pacific Medical Center
San Francisco, California
Syrentis Clinical Research
Santa Ana, California
St Joseph Heritage Healthcare
Santa Rosa, California
Stanford University Medical Center
Stanford, California
University Of Colorado Denver
Aurora, Colorado
IMMUNOe International Research Centers
Thornton, Colorado
Associated Neurologists of Southern Connecticut, PC
Fairfield, Connecticut
Yale University School Of Medicine
New Haven, Connecticut
Research Center for Clinical Studies, Inc.
Norwalk, Connecticut
JEM Research Institute
Atlantis, Florida
Bradenton Research Center, Inc.
Bradenton, Florida
Meridien Research
Brooksville, Florida
Quantum Laboratories Inc.
Deerfield Beach, Florida
Infinity Clinical Research, LLC
Hollywood, Florida
Mayo Clinic in Florida
Jacksonville, Florida
Renstar Medical Research
Ocala, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Axiom Clinical Research of Florida
Tampa, Florida
Emory University Cognitive Neurology Clinic & ADRC
Atlanta, Georgia
Medical Research Health and Education Foundation, Inc
Columbus, Georgia
NeuroStudies.net, LLC
Decatur, Georgia
Josephson, Wallack, Munshower Neurology, PC
Indianapolis, Indiana
McLean Hospital
Belmont, Massachusetts
Boston Center for Memory
Newton, Massachusetts
Hattiesburg Clinic, PA
Hattiesburg, Mississippi
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada
ActivMed Practices & Research
Portsmouth, New Hampshire
Showing 40 of 180 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.